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Abstract 
The history of IVF in humans from the early attempts in the USA through to the first 
definitive achievement of IVF by Edwards, Steptoe and Purdy (1969-1978), and the 
brief period of innovative IVF achievements to Melbourne, Australia, cut short by the 
passage of restrictive legislation (1979-1984) is recorded. A summary of the key 
achievements since the mid 1980s is then given. The shameful connotations of 
engaging in IVF of those esrly days is contrasted with its wide acceptance today, in 
which IVF is setting the norms for modern families.  
 
Introduction 
The history of mammalian IVF begins in 1930s USA, when Pincus famously, but 
controversially, claimed to have produced rabbit off-spring after fertilizing rabbit eggs 
in vitro (Pincus and Enzmann, 1934). Later, Rock and his research collaborator 
Miriam Menkin experimented on both fertilized and unfertilized eggs retrieved from 
patients during surgery, and in 1944 claimed the fertilization and cleavage in vitro of 
three human ova (Rock and Menkin, 1944). Then in 1951 Chang (1951) and Austin 
(1951) independently discovered capacitation, the requirement for sperm to undergo 
a series of surface changes in the uterus before they are capable of fertilizing the 
egg. This discovery led Austin (1961) to reevaluate the previous claims to have 
successfully fertilized eggs in vitro, producing five criteria which had not til that stage 
been satisfied: namely that, (1) capacitated sperm be used, (2) use of aged ova be 
avoided, (3) there be clear evidence that sperm had entered the ooplasm, (4) the 
possibility of parthenogenetic activation be excluded, and, ultimately, (5) the birth of 
young genetically identified as related to the transferred embryo(s) be forthcoming. 
Chang (1959), building on earlier work by Thibault et al. (Douzier and Thibault, 1959) 
and Moricard (1950), then went on to provide definitive proof of the success of IVF in 
mammals, by removing unfertilised ripe ova from a rabbit, fertilising them with 
capacitated sperm, incubating them, and transferring the resultant embryos to 
another rabbit, which gave birth to viable offspring. This demonstration was followed 
after 4 years by the successful fertilization of the hamster egg, but not its onward 
culture beyond the 2-cell stage (Yanagimachi and Chang, 1963, 1964). It was not 
until 1968 that the mouse egg was successfully fertilized in vitro, cultured to the 2-cell 
stage, at which time the 2-cells were transferred to the oviducts of recipient mice and 
in some cases went on to produce viable male and female 17.5 day fetuses that were 
genetically distinct from the host mother (Whittingham, 1968). During the 1950s and 
60s, a small number of scientists continued to pursue the elusive and controversial 
goal of IVF in humans (e.g. Petrov, 1958; Petrucci, 1961; Hayashi, 1963; Yang, 
1963). Among these was Landrum Shettles, a gynaecologist at Columbia University 
who claimed to replicate the techniques of Rock and Menkin in a series of 
experiments with retrieved human eggs, but convincing evidence of his success was 
never published (Shettles, 1955). In 1973, Shettles agreed to attempt IVF and 
embryo transfer (ET) for a Florida couple John and Doris Del Zio. His experiment 
was discovered by colleagues and terminated, leading to a lengthy court case and 
much negative publicity (Hennig, 2003). 
 
Edwards’ early work on egg maturation 
It was in this heated context of public debate over IVF and ET, and their potential 
application to humans, that in 1968 the Cambridge-based reproductive biologist 
Robert Edwards (Gardner, 2015) established a collaboration with the gynaecologist 
Patrick Steptoe (Edwards, 1996), who was a consultant in Oldham, Lancashire, and 
with Cambridge-based nurse-technician Jean Purdy (Johnson and Elder, 2015b). 
Edwards had previously worked on egg maturation with the underlying motivation to 
understand the origins of, and if possible to avoid, chromosomal anomalies such as 
Turner, Klinefelter or Down syndromes, which were first characterized 
chromosomally in 1959 (Ford et al., 1959; Lejeune et al., 1959; Jacobs and Strong, 
1959). Thus Edwards, working in the 1950s in Edinburgh, had studied the 
chromosomal dance that the meiotic mouse egg displayed between receiving the 
endocrine signal to ovulate and ovulation (Edwards and Gates, 1959). He was able 
to time this process precisely because, working with his wife Ruth Fowler (Fowler 
and Edwards, 1957), he had shown that it was possible to stimulate egg maturation 
in vivo by the appropriate hormonal administration to adult female mice – 
foreshadowing induced ovulation in women a few years later (Gemzell, 1962). After 
he left Edinburgh to work at the NIMR Mill Hill from 1958, he rediscovered the earlier 
findings of Pincus and Chang (Pincus and Saunders, 1939; Chang, 1955) that simply 
releasing the mouse egg from its follicle triggered the same meiotic maturation 
programme, suggesting that the follicle exercised a restraining influence on the egg, 
now known to be exerted by cAMP. This observation meant that, were the human 
egg to show the same spontaneous maturation on release from its follicle, then the 
opportunity to study this otherwise inaccessible process was a possibility. So 
Edwards spent the next 6 or so years trying to get eggs of various species, including 
the human, after their release from ovarian biopsies, to mature in vitro. It took a long 
time in part because no one then knew how long the interval was in the human 
between the rise in the level of the luteinising hormone (LH) inducing the initiation of 
ovulation and the reentry of the egg into meiosis through to second metaphase. It in 
fact takes considerably longer, around 36 hours in women, than was known for the 
more studied animals such as the rat or mouse in which it is only 12 hours, and had 
been reported erroneously by Pincus (Pincus and Saunders, 1939) to be of the same 
order in the human. However, in 1965 Edwards, who had relocated to the Physiology 
Department in Cambridge in 1963, was able to publish two papers (Edwards, 
1965a,b) describing the detailed time courses of the meiotic maturation of eggs in the 
mouse, cow, pig, sheep, rhesus monkey and the human. Indeed the paper in the 
Lancet (Edwards, 1965b) in which he describes the human results, he sets out the 
potential possibilities and difficulties that flowed from his work with astonishing 
foresight and imagination.  
The discussion in this paper also clearly identifies his then primary interest as 
not being the alleviation of infertility but the ability to study and thereby to avoid 
genetic disease (Johnson, 2011). Indeed, within 2-3 years he had demonstrated 
proof of principle of preimplantation genetic testing (PGT) for disease  in the rabbit 
embryo, over 20 years before PGT was achieved in the human (Gardner and 
Edwards, 1968). Likewise, working with Cambridge geneticist Alan Henderson, 
Edwards was to develop his ‘production line theory’ of egg production to explain the 
origins of increased levels of maternal aneuploidy in older women. Thus, the earliest 
mouse eggs to enter meiosis in the fetal ovary were shown to have more chiasmata 
(thereby being more stable) and to be ovulated earlier in adult life than the those 
entering meiosis later in fetal life (Edwards, 1970; Henderson and Edwards, 1968). 
 
The consequences of meeting with Steptoe 
It was only after meeting Patrick Steptoe in 1968 that Edwards was persuaded 
by him that IVF was a means of treating infertility for many couples (Johnson, 2011). 
This was unsurprising at that time, as in the 1960s, little was known in the UK about 
the incidence, causes and treatments of infertility (RCOG, 1967; MRC, 1969; 
Benninghaus, 2017; Davis, 2017), reproductive sciences focusing on the perceived 
problem of over-population (Connelly, 2008; Marks, 2001, p. 31, pp. 195–236). This 
scientific focus, whose practitioners included Edwards, who was then spending most 
of his time trying to induce immunity to spermatozoa as a potential form of 
contraceptive (Johnson, 2011), contrasted with that of Steptoe, who had a long term 
interest in treating the infertile. One of the main reasons that he had developed and 
pioneered use of laparoscopic surgery in the UK (Steptoe, 1967) was because he 
then could use the technique to see into the abdomen relatively non-invasively and 
thereby assess the likely cause of, and prognosis for, infertility in women. When 
Edwards first entered into a partnership with Steptoe, it was with the idea that 
Steptoe could help him to overcome the problem of sperm capacitation, with which 
Edwards had been struggling for 4 years (Edwards et al., 1966, 1968; Johnson, 
2011). Thus spermatozoa taken directly from the male ejaculate cannot fertilize the 
egg unless, as it was believed at that time, they have been capacitated by a period of 
exposure to the female genital tract fluids (Austin, 1951; Chang, 1951). Edwards had 
read a publication by Steptoe in which he claimed that he could recover sperm 
laparoscopically from the oviduct! So hey presto if he could do that, then the 
recovered spermatozoa could be used to fertilize eggs that Edwards had matured in 
vitro. However, the first fruits of their collaboration did not involve such sperm 
recovery, because Barry Bavister working in the Cambridge laboratory on hamster 
sperm capacitation, had found that sperm could achieve full fertilization capacity 
without going near the female tract by simply being exposed to raised pH (Bavister, 
1969), and Edwards found the same applied to human spermatozoa! So though 
Steptoe’s name appeared on the 1969 Nature paper, describing the first generally 
accepted account of successfully in-vitro fertilized human eggs (Edwards et al., 
1969), notwithstanding various disputed prior claims (Rock and Menkin, 1944; 
Shettles, 1955, pp. 505–510; Petrov, 1958; Petrucci, 1961; Hayashi, 1963; Yang, 
1963), Steptoe had not supplied many (or possibly any) of the eggs and neither had 
he suppIied the capacitated spermatozoa (Johnson, 2011).  
However, at that time, data were emerging that suggested that the maturation of 
eggs in vitro might allow the chromosomal dance to proceed, but did not result in 
ooplasmic maturation sufficient to support development. So the attention of Edwards, 
Steptoe and Purdy turned to the development of laparoscopic recovery of almost 
matured eggs from the follicles, thereby avoiding this problem. Table 1 indicates the 
range of then unsolved technical problems that confronted the three pioneers in their 
quest to produce a baby in this way. Undeterred, Edwards allied his extensive 
knowledge of the timing of oocyte maturation in vivo with the key technical innovation 
made by Steptoe – namely surgical use of the laparoscope. Use of this instrument 
enabled the collection of multiple oocytes, induced by injection of gonadotrophins 
(Gemzell, 1962), from the intact ovaries of patients under anaesthesia (Steptoe and 
Edwards, 1970). The laparoscopic approach (or key hole surgery) enabled superior 
visualization of the inner abdomen by using cold light conducted through a flexible 
fibre optic tube. The surface of the ovary could thus be clearly observed and the 
follicles containing eggs punctured with a thin hollow needle passing through the 
abdominal wall to enable egg collection by suction of the follicle contents – known as 
aspiration. Preliminary attempts at laparoscopic oocyte recovery (LOR) may have 
already commenced late in 1968, as reported in Edwards et al. (1969, p.635; 
published on 15 February, submitted December, 1968). During 1969 the main 
emphasis was on improving the timing and technique of laparoscopy and recovery of 
eggs after triggering oocyte maturation. Follicles were initially aspirated using a 
syringe and needle, but in September 1969 a “new suction gadget ” was introduced 
(Figure 1), which had a bypass valve that allowed the assistant to control suction, 
resulting in the collection of clearer follicular fluids. Having tested this suction device 
with a range of suction pressures, an ‘optimum’ pressure of no greater than 12 cm 
Hg, was settled on 'since higher pressures may damage the oocytes' (Elder and 
Johnson, 2015b).  
Determining the optimal timing of laparoscopic egg collection was a challenging 
but crucial component of successful IVF.  However, this phase of the research was 
accomplished fairly rapidly. Thus, the two important initial goals were to aspirate 
oocytes from their follicles just before ovulation was expected, and to have more than 
one pre-ovulatory oocyte available for aspiration. Injection of the gonadotrophic 
hormones, human menopausal gonadotrophin (HMG) to stimulate follicle growth, 
followed by human chorionic gonadotrophin (HCG) to induce terminal follicular 
maturation, was felt to be necessary in order to control the menstrual cycle and 
regulate follicle growth, oocyte maturation and ovulation. HCG was administered 
when an adequate concentration of urinary oestrogens was detected in 24-hour 
samples (>75 μg/day), but given to allow laparoscopic recovery at a suitable time 
(usually early in the morning or later at night as the staff were volunteers working 
outside their normal hours; Johnson and Elder, 2015c). By September1969 onwards, 
“a regimen of three injections of HMG between days 2 and 9, and 5000 IU of HCG on 
days 9–11 of the menstrual cycle was adopted as giving the best response” (Steptoe 
and Edwards, 1970). The interval between HCG and egg collection was also varied, 
and the duration of this interval was compared with the presence of corpora lutea to 
confirm whether or not ovulation had already taken place at the time of laparoscopy. 
At first, laparoscopy was carried out on days 10–12, with an initial interval between 
HCG and laparoscopy of 28.75–29.50 h, increased to 29.50–30.00 h from mid-
January 1970, and then to 32.0–33.5 h in mid-March 1970 (Elder and Johnson, 
2015b). Most eggs recovered during 1969, when the average yield per follicle was 
only 33%, were examined for their normality cytologically or chromosomally, but 
many were found to be immature. This finding led them to culture the recovered eggs 
in drops of their own follicular fluid (wherever was possible) for 1-4 hours before they 
were inseminated in vitro with in-vitro capacitated sperm in a modifed medium 
developed for his hamster fertilization studies by Barry Bavister initially, although 
later moving to an Earle’s based medium, both at pH 7.55. From 1970 approximately 
50% of follicles yielded eggs, and the first attempted fertilization of eggs is described 
as being on 23 October and 21 to 24 November 1969 (Elder and Johnson, 2015a). 
Between 1969 and 1971, Edwards, Steptoe and Purdy successfully achieved 
cleavage and blastocyst formation in vitro (Edwards et al., 1970; Steptoe et al., 
1971), and in December 1971 commenced transfer of embryos (mostly at the 8-16 
cell stage) to women to try and achieve pregnancy (Elder and Johnson, 2015a). 
 
The problem of implantation 
Despite the long history of scientific and technological innovation preceding them, 
and their own innovations, Edwards, Steptoe and Purdy struggled to achieve 
successful implantation, and it was almost a decade from the first successful 
fertilization of a human egg in vitro in 1969 to the birth of Louise Brown in 1978 
(Edwards and Steptoe, 1978). The problems were twofold: (1) they did not know 
whether the embryos that they were putting back had the potential to develop further, 
and (2) they were unsure whether the right hormonal conditions for implantation were 
vitiated by the hormonal stimulation required to induce multiple follicles to mature. 
With regard to the first uncertainty, they had considerable experience with animal 
embryo culture by which to be encouraged. Thus, by the 1950s it had been 
established that the culture of mouse embryos from the 8-cell stage to the blastocyst 
required glucose (Hammond, 1949; Whitten, 1956) and that their transfer to recipient 
uteri could result in live young (McLaren and Biggers, 1958). By the early 1970s it 
had become clear that mouse 2-cell embryos recovered from the female tract could 
also be cultured successfully in vitro to blastocyst stage and then transferred to the 
uterus with the production of live young (Cholewa  and Whitten, 1970) and that some 
mouse embryos could even be cultured to the blastocyst stage from the pronuclear 
stage and live young result (Whitten and Biggers, 1968). Moreover, it had also been 
established that culture from the 2-cell stage to the 8-cell stage required lactate or 
pyruvate (Whitten, 1957; Brinster, 1965a,b). Brinster (1963) had also introduced a 
revolutionary method for culturing mouse embryos in small drops of medium under 
paraffin oil rather than in the larger volume test tubes, as had been done previously, 
an approach adopted by Edwards from January 1970 (Elder and Johnson, 2015b). 
Notwithstanding these advances in culture conditions and media, which Edwards 
could build on, it was also clear that most embryos of most species examined 
blocked during in-vitro culture from the 1-cell stage at a stage characteristic for the 
species, which later turned out to coincide with the species-specific time of major 
activation of the embryo’s genes. This had limited the successful use of IVF in 
animals. In addition, it had also been found that the premature transfer of animal 
embryos to uteri at a stage earlier than the embryos would be transported there 
naturally, resulted in the death of the embryos. If either of these situations had 
applied to the human, it would have made the task of Edwards harder. Fortunately, 
no evidence of a block to development was found to occur in the human, and 
Marston et al. (Marston et al., 1977), found that the requirement for synchrony was 
not as rigorous in the primate as in the rodent. In fact, Edwards, aside from adopting 
a modified version of Bavister’s medium for the fertilization phase, chose to largely 
ignore the work on mouse embryo culture in his choice of media, using more 
complex media involving bovine or serum albumen, or fetal calf serum, or the 
patient’s follicular fluid or serum. Thus, by the end of 1970, he was using variants of a 
Tyrode’s B based medium for sperm and egg washing and fertilization, and a Ham’s 
F10 and F12 based medium for cleavage culture (Elder and Johnson, 2015b), both 
with the accompanying macromolecular fluids. However, their success in culturing 
embryos to the blastocyst stage caused the team to turn their attention to the luteal 
phase endocrine conditions on which they then focussed. 
 This problem was less tractable (Elder and Johnson, 2015a,b). Thus, despite 
transferring embryos from 1972 onwards, they only got the first evidence of a clinical 
pregnancy in 1975, but this turned out to be ectopic, a biochemical pregnancy 
(detected via a transient rise in HCG blood levels) occurring the following year (Elder 
and Johnson, 2015a). Edwards was aware that high levels of oestrogen in the 
follicular phase, induced by the higher repeated doses of HMG being used, were 
unfavourable for the luteal phase endometrium and indeed shortened the luteal 
phase, and so attempts were made at the beginning of 1973 to reduce the high 
oestrogen levels by replacing for some patients HMG stimulation with clomiphene-
stimulated cycles + HCG to induce follicular maturation. However, these cycles 
resulted in very low egg recovery rates and so were abandoned (Elder and Johnson, 
2015b), and the use of HMG restored from 1975 to 1977. Provision of exogenous 
luteal support was attempted by luteal administration of Pregnyl, first tried in October 
1972, or of both Pregnyl and intramuscular progesterone, during 1973–74, with the 
addition of Primolut depot (hydroxyprogesterone hexanoate) in July 1975, along with 
occasional use of Ritodrine, Indocid, and Ethinyl Estradiol supplementation. With the 
finding that prolactin was elevated in many patients, daily bromocryptine was added 
from the mid-follicular phase and throughout the luteal phase between February and 
July 1977. However, these attempts were without success, and the decision was 
taken towards the end of 1977, to avoid the use of exogenous hormones altogether 
and thereby the accompanying adverse effects on oestrogen levels and the luteal 
phase. This introduction of natural cycles in parallel with more detailed endocrine 
monitoring meant a reduction in the numbers of eggs recovered, but with better 
overall success in retrieving competent preovulatory oocytes for successful IVF 
(Elder and Johnson, 2015b), that led to the birth of Louise Brown. This success, 
together with the second birth that followed it in 1979 plus two miscarriages (Elder 
and Johnson, 2015b), were achieved via the collection of the one egg destined to be 
naturally ovulated each cycle. This procedure involved the regular collection of urine 
samples every three hours, in which the rising level of LH was assayed to guide the 
time of laparoscopic egg recovery before natural ovulation could occur – a 
considerable achievement!  
In addition to this wide range of clinical and scientific problems, Edwards, 
Steptoe and Purdy also faced constant ethical objections to their work, to which they 
responded robustly (e.g. Edwards and Sharpe, 1971; Edwards, 1974), and 
proceeded under near constant critical scrutiny by both the media and their clinical 
and scientific colleagues (Johnson et al., 2010; Johnson, 2018).  
 
Enter Australian medico-scientists   
Edwards, Steptoe and Purdy’s successes in 1978 and 1979 opened the door to the 
rapid clinical expansion of IVF and embryo transfer, through which millions of IVF 
babies have been born world-wide. However, because the three pioneers had to 
relocate from Oldham on account of Patrick Steptoe having reached retirement age, 
and because this relocation was not supported by either the NHS or Cambridge 
University, there was an enforced hiatus in their work until 1982 as they sought 
private premises and built the necessary infrastructure at Bourn Hall in 
Cambridgeshire. During this period the initiative passed to Melbourne in Australia, 
where two groups had been working on IVF since the early 1970s stimulated to do so 
by Edwards’ 1969 demonstration of successful IVF. And it was in Melbourne that the 
next clutch of IVF births occurred, the first using the natural cycle approach 
successfully used by Edwards and his colleagues (Lopata et al., 1980). In Melbourne 
a significant advance was made in the successful use of hormonal control of 
ovulation by use of clomiphene citrate with or without a dose of HCG in the recovery 
of eggs for IVF (Trounson et al., 1981; and soon followed by the successful use in 
the USA of HMG and HCG; Coddington and Oehninger, 2018), the first use of egg 
donation (Trounson et al., 1983) occurred, and embryo freezing was used 
successfully to generate a pregnancy for the first time (Trounson and Mohr, 1983). 
However, this period of Australian dominance was cut short by the introduction in 
1984 of ambiguous and restrictive legislation by the state of Victoria that inhibited the 
inventive environment that had existed hitherto. Thus, IVF was initially a joint 
enterprise, allegedly stimulated in 1970 through conversations with Edwards (Wood 
& Westmore, 1984, p.43) between Carl Wood and John Leeton at Queen Victoria 
Hospital (QVH) associated with Monash University, and, from 1972 by Ian Johnston 
and James Brown at Royal Womens’ Hospital (RWH) associated with Melbourne 
University (McCalman, 1998, p.358). These clinicians were joined in 1971 by 
embryologist, Alex Lopata, when the work got seriously underway. This formidable 
Australian team reported their first two IVF biochemical pregnancies in 1973 (De 
Kretser et al., 1973), but neither progressed (Wood & Westmore, 1984, p.44).  In 
1977, Alan Trounson joined Wood’s team at Monash. Trounson was a graduate of 
Sydney University (1968-74), who had undertaken post-doctoral training (1974-76) in 
Cambridge at the ARC Animal Research Station, Huntingdon Road, where he had 
learnt about egg maturation, fertilization in vitro and embryo transfer and freezing in 
cows and sheep, and where he had also met Edwards. Then in 1979, the first on-
going pregnancy was reported in a patient at Melbourne RWH, the world’s third 
confirmed test tube baby being born in June, 1980 (Lopata et al., 1980). However, 
the publicity, which that hospital received upset the Monash team, and led to a split 
between the two clinics (with Wood and Trounson at Monash, and Johnston and 
Lopata at Melbourne; Kannegiesser, 1988; Wood and Westmore, 1984, p.46). This 
split was to have adverse consequences for legislative regulation, as was the almost 
universal initial hostility of the Australian medical profession and funding bodies 
(McCalman, 1998, p.361).  
However, by early 1982, Australian medical attitudes had softened, and a federal 
body, the National Health and Medical Research Council (NHMRC, 1982), produced 
guidance as part of its “Statement on Human Experimentation”, which inter alia 
offered cautious support for research using human embryos as well as the use of IVF 
for treating infertility (Szoke, 2004, pp. 263, 269-70). This support was followed later 
by ethical guidance on how to pursue IVF and research on human embryos 
(NHMRC, 1986). However, these federal interventions stimulated further vociferous 
public criticism in the catholic dominated state of Victoria. For example, late in 1981, 
the roman catholic Archbishop of Melbourne sent a telegram to the prime minister of 
Victoria: “Respectfully request review of [rumoured] grant being used for such callous 
immoral experiments on human beings” (Waller, 1992, p.19). Partly to deflect these 
criticisms, and also to provide protection for themselves, Wood requested that QVH 
establish an ethics committee, which Louis Waller, professor of law at Monash (1965-
2000), joined in 1981. Wood also asked the State Government to “institute a formal 
inquiry into the ethics of in vitro fertilisation” (McCalman, 1998, p. 81), which was duly 
announced in March 1982, and followed on 25th May 1982 with the information that it 
was to be chaired by Waller (Waller, 1990). Within 3 months it produced an interim 
report, which stated that the “the procedures were acceptable and their unanimous 
view was that the appropriate way to regulate the new developments was by 
legislation” (Szoke, 2004, p. 273). There then followed an ill-advised action by the 
team at Monash that cast doubt on their responsibility. Thus, Wood, having 
announced in the Age (news paper) the first use of egg donation to massive public 
criticism, was requested by the state Premiere and Attorney General to discontinue 
their work in this area “until the report on the use of donor gametes was finished and 
the legal issues resolved”. However, the team transferred their work in 1982 from a 
state hospital to the private Epworth Hospital, where it continued, allegedly due to 
Trounson’s furious reaction (Szoke, 2004, p.275-6; Kannegiesser, 1988, p.86). 
Dismayed by this action, the Victorian Government pressured Waller to a rapid 
conclusion, which occurred with the introduction of the Infertility (Medical Procedures) 
Bill in March 1984, before Waller had time to consider the issue of research on 
embryos (Szoke, 2004, p. 288), and also the year that the Warnock  committee (set 
up by the UK government in 1982 to investigate the regulation of IVF in the UK) 
reported and six years before the HFE Act based on it was passed into law in the UK. 
A key consequence of this rush to legislate in Victoria, which was completed in 1984, 
was that there was little opportunity there to engage the public and MPs in an 
educational process, nor for alliance building to achieve this outcome (Szoke, 2004, 
p. 307), as occurred in the UK. This deficiency was exacerbated by the fact that the 
two clinics involved in development of IVF saw each other as competitors and so did 
not work together effectively to recruit wider support, particularly critical in that 
women’s liberation groups joined forces in opposition in an ‘unholy’ alliance with the 
catholic church (Rowland 1984; Klein, 1989), an adverse feminist reaction that was 
not mollified by the uncompromisingly combative style adopted by the medical teams 
(Szoke, 2004, p.279-280). The outcome was legislation that included restrictions on 
treatment to married couples and on embryo research that significantly restricted the 
scope of research work in Victoria (Szoke, 2004 p. 297). This legislation, combined 
with political pressure from the State government, led to the movement out-of-State 
by some of the key players (Leeton, 2013; Wilton, 2018). 
 
Subsequent developments 
Since then there have been changes to the technique of egg aspiration, which is now 
achieved under local anaesthesia by ultrasound guidance (Lenz and Lauritsen, 1982) 
via the vaginal vault (Wikland et al., 1985), to embryo culture methods permitting 
successful culture to the blastocyst stage (Gardner and Lane, 1998), as well as to 
embryo selection criteria and cryopreservation techniques that have reduced the 
transfer of multiple embryos and so the problems attendant on multiple births 
(Racowsky et al., 2010). Freezing of oocytes has been possible since 1996 and has 
become more common in the past 5 years with the introduction of vitrification (Cobo 
et al., 2010). Moreover, the introduction in 1992 of Intra-Cytoplasmic Sperm Injection 
(ICSI; Van Steirteghem et al., 1993) revolutionized treatment of male infertility. 
Despite the proof of principle for PGT being established in 1968 (Gardner and 
Edwards, 1968), it was only in 1986 that clinical interest was roused and the pace of 
research quickened (Theodosiou and Johnson, 2002) such that the first PGT 
pregnancies were reported in 1990 (Handyside et al., 1990). Moreover, it is only over 
the past 10 years that PGT has taken off clinically, especially in the United States.  
Three technical approaches to PGT biopsy have been applied to four types of 
clinical application (Wilton, 2018). Post-fertilization, either a trophoblast biopsy from a 
day 5 blastocyst is used, or, now less commonly used, one or two blastomeres were 
biopsied from a day 2 or day 3 cleaving embryo. Pre-fertilization sampling of the 
polar body can be used to identify genetic problems in eggs (Verlinsky et al., 1997), 
but is no longer commonly used. Each sampling method has advantages and 
disadvantages in terms of sensitivity and reliability. The sampling technique used can 
also depend on the purposes for which the diagnostic test is being undertaken, that 
include: (1) sexing of embryos to avoid transmission of sex-linked genetic disease 
(Handyside et al., 1990) or, more controversially, and illegally in some jurisdictions, 
for family balancing. (2) The detection of a growing number of (mostly rare) single-
gene defects in the embryo is now possible. PGT for monogenic disease (PGT-M) 
offers a way to establish a pregnancy, confident that a disease-free child will be born, 
thereby avoiding the distress of an affected birth or the consideration of a later 
termination (Handyside et al., 1992). For early-onset severe or lethal diseases, the 
use of PGT-M is relatively noncontroversial ethically. However, increasingly PGT-M 
is being considered for late-onset, variably penetrant, and less severe conditions. It is 
also possible, but illegal in most jurisdictions, to use PGT to select for certain genes, 
either for genes conferring an affected phenotype to match a parental condition (e.g., 
deafness or dwarfism) or to confirm parental choice – so-called ‘designer babies’. (3) 
Chromosomal anomalies, such as errors of somy, ploidy, and complex 
translocations, can be detected by preimplantation genetic testing for aneuploidy 
(PGT-A; Gianaroli et al., 1997). In some clinics, the use of PGT-A in all women, in 
older women, or in women who have experienced repeated pregnancy loss is 
controversially becoming almost routine. However, randomized control trials have not 
provided unequivocal evidence of its beneficial value for widespread or even for 
selective use (Verpoest et al., 2018), especially given the uncertainty generated by 
the finding of extensive mosaicism in many blastocyst biopsies (Gleicher, 2018; 
Braude, 2018). (4) PGT has also been used to produce so-called ‘savior siblings’, in 
which an embryo is typed for histocompatibility with an existing sibling who has a 
disease requiring a tissue graft – provided by the cord blood cells from the ‘savior 
sibling’ (Verlinsky et al., 2001). Each of these applications of PGT raises ethical 
issues, and the legal response to consideration of these issues has been very varied 
in different countries. 
The technology used for the genetic diagnosis of a biopsied sample is also varied 
and tailored to the purpose for which the test is being used. Initially, two types of tests 
were used: (i) fluorescent in situ hybridization (FISH) to detect abnormal karyotypes, 
structural chromosomal anomalies, or embryo sex (Griffen et al., 1993) and (ii) various 
types of polymerization chain reaction (PCR) for single-gene detection (Handyside et 
al., 1990). Recent improvements in whole-genome amplification (WGA) and array 
technologies are revolutionizing detection methodology. WGA facilitated PCR-based 
chromosomal testing (Wells et al., 1999), and its use has proved promising in 
conjunction with two types of array that have been developed: array comparative 
genomic hybridization (aCGH: LeCaignec et al., 2006) and single-nucleotide 
polymorphism (SNP)-based arrays. Both array types can be used to determine 
anomalous chromosome number, but only SNP-based arrays can be used for 
haplotyping the samples. These techniques are being superceded by use of next 
generation sequencing (NGS) approaches that provide a more automated and 
therefore less expensive approach than array CGH. Handyside et al. (2010) have used 
karyomapping, which involves bioinformatic analysis of SNP array data to allow both 
single gene errors (PGT-M) in combination with many errors in ploidy to be detected 
in the same biopsy samples. And soon even biopsy may not be necessary by sampling 
the DNA released into the culture medium by embryos (Palini et al., 2013). 
In addition to PGT, modification of the genetic composition of embryos has also been 
reported. Reproductively in the case of mitochondrial transfer, in order to counteract 
the presence of faulty mitochondria, by which technique a single child has been born 
thus far (Zhang et al., 2017), in somewhat controversial circumstances (Alikani et al., 
2017), although the HFEA has now licensed this approach under strict conditions for 
use in the UK. A number of laboratories have also used a CRISPR/Cas9-mediated 
gene editing approach to modify the genetic composition of human eggs for 
experimental purposes only (Liang et al., 2015; Fogarty et al., 2017; Schenkwein and 
Yia-Herttuala, 2018), and recently Japan has promised draft guidelines on the use of 
the technique experimentally that will be open for public comment from November 
2018 and are likely to be implemented in the first half of next year (Cyranoksi, 2108). 
Currently, the use of the technique reproductively is legally banned in the UK, but not 
in the USA or China. 
IVF has also permitted the production of human embryonic stem cells (ESCs) in 
1998 (Thomson et al., 1998), following their successful derivation in rabbits by 
Edwards, with Robin Cole and John Paul (Cole et al., 1966) and in mice by Evans and 
Kaufman (1981) and Martin (1981). In combination with somatic cell nuclear transfer 
(SCNT, first described successfully for sheep in 1996; Campbell et al., 1996), the use 
of ESCs allows the production of pluripotent cell lines matched genetically to the 
nuclear donor. This approach opens the possibility of tissue repair and cell therapy. 
However, the use of other sources of pluripotent cell lines, such as induced stem cells 
(Takahashi and Yamanaka, 2006), may turn out to be ethically more acceptable and 
practically less demanding. 
   Recently, human embryos have been cultured in vitro in a matrix that has 
allowed them to develop for up to 12-13 days, approaching the legally-permitted limit 
of 14 days in the UK. Surprisingly, the embryos seem to undergo normal 
morphogenesis, forming a proamniotic cavity in the absence of any maternal input, 
suggesting that the pattern of early development resides entirely within the embryo 
itself (Deglincerti et al., 2016). Such in vitro implanted embryos may be able to 
develop for another 1-2 weeks thereby permitting the study of the generation of the 
primitive streak and the gametes (germ line) in vitro, subject to a change in the law. 
Even without a change in the law, the study of in-vitro implantation over the period of 
gastrulation by use of human embryo-like entities may be possible, as recently use of 
aggregates of mouse ES cells have been found to function in many respects 
comparably to embryos up to pregastrulation stages in mouse (Bedzhov and 
Zernicka-Goetz, 2014). When trophoblast stem cells are also added better 
development is observed (Harrison et al., 2017), and the addition of a third cell line, 
equivalent to the hypoblast in the mouse, has taken the embryos through a quasi 
gastrulation with the formation of germ cells (Sozen et al., 2018). For humans, where 
only ESC lines exist at present (equivalent to epiblast), development of embryo-like 
structures is becoming possible (Shahbazi and Zernicka-Goetz, 2018) meaning that 
discovery of hypoblast and trophoblast human stem cell lines is pressing. 
Finally, a recent development has promised to bring IVF to the poorer members 
of society, with the demonstration that the whole procedure can be conducted more 
simply and thus more cheaply, in the “walking egg project’ (van Blerkom et al., 2014) 
– a development that would have appealed to the egalitarian values of Bob 
Edwards.This system reproducibly generates de novo the atmospheric and culture 
conditions that support normal fertilization and preimplantation embryogenesis to the 
hatched blastocyst stage without the need for specialized medical-grade gases or 
equipment. Development from insemination to the hatched blastocyst stage occurs 
undisturbed in a completely closed system that enables timed performance 
assessments for embryo selection in situ that, in this study, involved single-embryo 
transfers on day 3. With the simplified culture system, 8 of 23 embryos that were 
transferred implanted, one miscarried at 8 weeks of gestation and seven healthy 
babies were born.  
Conclusions 
From its early contested beginnings, IVF now offers a range of technical possibilities 
that theoretically allow us to control the reproductive process in many ways. This 
modern technology is also changing the meaning of families; thus dead mothers and 
fathers can still produce genetic offspring, two mothers or two fathers can parent a 
child, indeed the meaning of the terms father and mother has changed and 
multiplied. IVF has also become so normalized compared with the early days, when 
its use was considered shameful, that now it sets the standard for natural methods of 
reproduction (Franklin, 2013). Truly, Edwards, Steptoe and Purdy started a scientific 
and social revolution with their pioneering discovery of IVF, for which in 2010 
Edwards was awarded the Nobel Prize for Physiology and Medicine ‘for the 
development of in vitro fertilization’ (Nobel, 2010).  
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Table 1 Some of the medico-scientific challenges that had to be overcome before the 
first successful live birth following IVF and embryo transfer was achieved. 
Challenges 
Technical aspects of follicle aspiration (‘new suction gadget’- see figure 1) 
Ovulation induction 




Sperm preparation and capacitation 
Insemination procedure: medium, timing 
Culture for embryo cleavage: medium, assessment 




Legend to figure 1 
Photographs of the “suction device” invented by Edwards and Steptoe (1975) – a 
simple aspirator for withdrawing the contents of human follicles. A vacuum applied at 
the wide arm (E) is directed through the needle (F) when required by simply blocking 
the open Y-arm (B) in the aspirator. Oocyte and follicular fluid are withdrawn through 
the needle and its lead (D) into the collecting pot (A), which can easily be removed 
from the neoprene bung (C) and replaced.  
 
     
